Using multiple breast cancer cell line models, we show that LDHC is involved in maintaining mitotic fidelity and genomic integrity and that targeting of LDHC improves treatment response to DNA damage response targeted therapy using DNA damage inducers and DNA repair inhibiting agents. The gene discussed is LDHC; the disease is breast cancer.